Get started
Author

Laura Popper

Observed name: LAURA POPPER
Observed institution: Mapi Pharma (Israel)
OpenAlex ID: A5075574527
Glatiramer Acetate Depot (extended-release) phase IIa study in patients with Primary Progressive Multiple Sclerosis: safety and efficacy snapshot (1911)
2021 · Shlomo Flechter, Laura Popper, et al. · Neurology · 2
Glatiramer Acetate Depot (extended-release) Phase IIa one-year study in patients with Relapsing-remitting Multiple Sclerosis: Safety, tolerability and efficacy – NEDA Analysis (P6.359)
2018 · Ariel Miller, Laura Popper, et al. · Neurology · 2
GA Depot (Long-acting IM Injection of Glatiramer Acetate) Presents Improved Safety and Tolerability Features: Results from a Multinational, Double-blind, Placebo-controlled Phase III Study in Subjects with Relapsing Forms of Multiple Sclerosis (P8-6.018)
2024 · Aaron Miller, Laura Popper, et al. · Neurology · 1
GA Depot (Long-acting IM Glatiramer Acetate) and its Impact on EDSS in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) (P7-19.002)
2026 · Aaron Miller, Laura Popper, et al. · Neurology
GA Depot, a long-acting glatiramer acetate, vs placebo in patients with relapsing multiple sclerosis: A randomized phase 3 clinical trial
2026 · Aaron Miller, Jeffrey A Cohen, et al. · Multiple Sclerosis Journal
PDF
GA Depot (Long-acting IM Injection of Glatiramer Acetate) Impact on EDSS Stability in Relapsing Forms of Multiple Sclerosis (RMS) and Primary Progressive Multiple Sclerosis (PPMS) (P11-1.014)
2025 · Aaron Miller, Laura Popper, et al. · Neurology
2052-LB: Semaglutide Depot, a Long-Acting Injection of Semaglutide Administered Once Every Four Weeks, Demonstrates Similar Efficacy and PK Profile to Daily Semaglutide Administration
2024 · SHAI RUBNOV, GALINA ZATS, et al. · Diabetes
Results of a Phase III, Multinational, Double-blind, Placebo-controlled Study in Subjects with Relapsing Forms of Multiple Sclerosis (RMS) to Assess the Efficacy, Safety, and Tolerability of GA Depot, a Long-Acting IM Injection of Glatiramer Acetate, Administered Once Every Four Weeks (P6-3.014)
2023 · Aaron Miller, Laura Popper, et al. · Neurology
Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Primary Progressive Multiple Sclerosis: Safety and Efficacy Snapshot (P7-4.001)
2022 · Shlomo Flechter, Laura Popper, et al. · Neurology
Five Years Analysis of anti-Glatiramer Acetate (GA) Antibodies in Patients with Relapsing Remitting Multiple Sclerosis Treated with GA Depot (P5-4.010)
2022 · Shlomo Flechter, Ariel Miller, et al. · Neurology
Glatiramer Acetate Depot (extended-release) phase IIa study in patients with primary progressive multiple sclerosis: safety and efficacy snapshot (1956)
2020 · Shlomo Flechter, Laura Popper, et al. · Neurology
Glatiramer Acetate Depot (extended-release) phase IIa study in patients with relapsing remitting multiple sclerosis: safety, tolerability and efficacy (No Evidence of Disease Activity) subpopulation three-years analysis (1936)
2020 · Shlomo Flechter, Ariel Miller, et al. · Neurology
Glatiramer Acetate Depot (Extended-Release) Phase IIa Study in Patients with Relapsing Remitting Multiple Sclerosis: Safety, Tolerability and Efficacy (No Evidence of Disease Activity) Two-Years Analysis (P3.2-052)
2019 · Shlomo Flechter, Ariel Miller, et al. · Neurology
Works count: 13
Citation count: 5
H-index: 2
I10-index:
Year
Topic
Type